Table 1.

Clinical baseline characteristics of patients. Patient characteristics are presented as total number (n) and percentage of all (%)

	Total (%)
Total	509
Age (years)
Median	60.8 (range 27 to 86 years)
Menopausal status
Premenopausal Perimenopausal Postmenopausal	72 (14.1) 63 (12.4) 374 (73.5)
Histology
Ductal Lobular Others	385 (75.6) 68 (13.4) 56 (11.0)
Tumor stage
pT1 pT2 pT3–4 pTis Unknown	321 (63.1) 160 (31.4) 24 (4.7) 3 (0.6) 1 (0.2)
Nodal status
Node negative Node positive Unknown	340 (66.8) 167 (32.8) 2 (0.4)
Grading
I II III Unknown	89 (17.5) 270 (53.0) 149 (29.3) 1 (0.2)
ER status
Negative Positive Unknown	94 (18.5) 414 (81.3) 1 (0.2)
PR status
Negative Positive Unknown	135 (26.5) 373 (73.3) 1 (0.2)
Her2 status
Negative Positive Unknown	426 (83.7) 80 (15.7) 3 (0.6)
Immunohistochemical subtype
(ER-, PR-, Her2-) (ER-, PR-, Her2 +) (ER + and/ or PR + , Her2-) (ER + and/ or PR + , Her2 +)	65 (12.8) 23 (4.5) 364 (71.5) 57 (11.2)
DTC status
Positive Negative Unknown	207 (40.7) 300 (58.9) 2 (0.4)

Adapted and modified from Rachner et al. (2018) and Rachner et al. (2020)